These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29524943)

  • 1. The Conceptualization of Value in the Value Proposition of New Health Technologies Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
    Buttigieg SC; Hoof JV
    Int J Health Policy Manag; 2018 Feb; 7(2):186-188. PubMed ID: 29524943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Health Technologies: A UK Perspective Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
    Parvizi N; Parvizi S
    Int J Health Policy Manag; 2017 Dec; 6(12):721-722. PubMed ID: 29172379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.
    Lehoux P; Miller FA; Daudelin G; Denis JL
    Int J Health Policy Manag; 2017 Sep; 6(9):509-518. PubMed ID: 28949463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bright Elusive Butterfly of Value in Health Technology Development Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
    Greenhalgh T; Fahy N; Shaw S
    Int J Health Policy Manag; 2018 Jan; 7(1):81-85. PubMed ID: 29325407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Co-Constitution of Health Systems and Innovation Comment on "What Health System Challenges Should Responsible Innovation in Health Address? Insights From an International Scoping Review".
    Peine A
    Int J Health Policy Manag; 2019 Nov; 8(11):665-667. PubMed ID: 31779292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovation Strategies and Health System Guiding Principles to Address Equity and Sustainability in Responsible Innovation in Health Comment on "What Health System Challenges Should Responsible Innovation in Health Address? Insights From an International Scoping Review".
    Buttigieg SC
    Int J Health Policy Manag; 2019 Sep; 8(9):570-572. PubMed ID: 31657182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving low value care lists into action: prioritizing candidate health technologies for reassessment using administrative data.
    Soril LJJ; Seixas BV; Mitton C; Bryan S; Clement FM
    BMC Health Serv Res; 2018 Aug; 18(1):640. PubMed ID: 30111308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the Internet in scanning the horizon for new and emerging health technologies: a survey of agencies involved in horizon scanning.
    Douw K; Vondeling H; Eskildsen D; Simpson S
    J Med Internet Res; 2003; 5(1):e6. PubMed ID: 12746211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling in Early Stages of Technology Development: Is an Iterative Approach Needed? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Drummond MF
    Int J Health Policy Manag; 2020 Jun; 9(6):260-262. PubMed ID: 32613795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurturing Societal Values in and Through Health Innovations Comment on "What Health System Challenges Should Responsible Innovation in Health Address?".
    Abrishami P; Repping S
    Int J Health Policy Manag; 2019 Oct; 8(10):613-615. PubMed ID: 31657189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Forecasting medical technologies--a global overview].
    Tal O
    Harefuah; 2011 Feb; 150(2):185-9, 202. PubMed ID: 22164951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing responsible innovation in health: a policy-oriented framework.
    Pacifico Silva H; Lehoux P; Miller FA; Denis JL
    Health Res Policy Syst; 2018 Sep; 16(1):90. PubMed ID: 30200985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming Disciplinary Traditions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Lehoux P; Silva H
    Int J Health Policy Manag; 2020 Jul; 9(7):309-311. PubMed ID: 32613802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioethics, health technology reassessment, and management.
    Soril LJ; Clement FM; Noseworthy TW
    Healthc Manage Forum; 2016 Nov; 29(6):275-278. PubMed ID: 27744278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Innovation in health care: the role of HTA in the introduction of new technologies].
    Bührlen B
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):703-8. PubMed ID: 21147431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.